Table 3.
Plasma | |||
---|---|---|---|
Strains Used for the Infection | LF (log10 pg/mL) | EF (log10 pg/mL) | LF/EF (log10) |
9602WT-lux | 3.42 ± 0.06 (17) | 0.74 ± 0.03 (10) | 2.64 ± 0.12 (8) |
9602P-lux | 3.01 ± 0.08 (7) | 0.86 ± 0.05 (28) | 1.97 ± 0.09 (6) |
9602P-lux + 1 µg PA | 3.75 ± 0.02 (12) | 1.19 ± 0.1 (9) | 2.56 ± 0.09 (9) |
9602P-lux + 10 µg PA | 3.55 ± 0.04 (14) | 1.04 ± 0.09 (13) | 2.52 ± 0.13 (11) |
9602LC +10 μg (EF + LF) | 3.88 ± 0.08 (16) | 0.97 ± 0.08 (10) | 2.85 ± 0.15 (10) |
Abbreviations: EF, edema factor; LF, lethal factor; PA, protective antigen; SEM, standard error of the mean.
aMice were intranasally challenged as described in Table 1. The EF and LF concentrations were assessed by competitive immunoassay and mass spectrometry, respectively, in the plasma 1 hour after challenge and compared with the threshold obtained with the plasma of noninfected mice. The EF and LF concentrations are expressed as the mean log10 ± SEM pg per mL in the plasma. The LF/EF ratio was calculated for each individual mouse displaying values over the thresholds for both LF and EF in the plasma. Data are expressed as the mean log10 ± SEM. (n), number of samples.